Caenorhabditis elegans as an in vivo model to assess fucoidan bioactivity preventing Helicobacter pylori infection. Issue 5 (12th May 2020)

• Record Type: Journal Article
• Authors: Palacios-Gorba, Carla; Pina, Raquel; Tortajada-Girbés, Miguel; Jiménez-Belenguer, Ana; Siguemoto, Érica; Ferrús, Maria Antonia; Rodrigo, Dolores; Pina-Pérez, Maria Consuelo
• Is Part Of: Food & function. Volume 11:Issue 5(2020)
• Page Start: 4525
• Page End: 4534
• Publication Date: 2020-05-12
• Subjects: Food -- Analysis -- Periodicals; Food -- Composition -- Periodicals; Nutrition -- Periodicals; 664.07
• DOI: 10.1039/d0fo00768d
• Languages: English
• ISSNs: 2042-6496

Abstract

Abstract : Fucoidan effectively reduces H. pylori infection. Abstract : Currently, Helicobacter pylori is the unique biological carcinogenic agent. The search for antimicrobial alternatives to antibiotics against this pathogen has been categorized as a priority due to the drastic failure associated with current applied antibiotic therapy. The present study assessed the bioactive antimicrobial capability of fucoidan ("Generally Recognized as Safe" approval – European Commission December 2017) from different species of Phaeophyceae algae ( Fucus vesiculosus, Undaria pinnatifida, Macrocystis pyrifera ) against H. pylori . All the studied fucoidans showed bacteriostatic and bactericidal effects at the studied concentrations [5–100] μg ml −1 and exposure times [0–7 days]. The most effective anti- H. pylori fucoidan was validated in Caenorhabditis elegans as an in vivo model. C. elegans feed was supplemented with Undaria pinnatifida [0–100] μg ml −1 fucoidan, resulting in a significant improvement in lifespan, lowered H. pylori concentration in the digestive tract, and increased egg-laying pattern. New research lines proposing this compound as an active agent in nutraceutical and preventive novel therapies should be opened.